Key result
Each 1 mmHg decrease in systolic blood pressure at 24 hours was associated with increased risk of 30-day death, worsening HF, or HF readmission (HR 1.01; 95% CI 1.00-1.02; P=0.021).
Why the study?
Does systolic blood pressure decrease during the first 24 hours of acute heart failure admission increase the risk of adverse outcomes?
RCT (n=1,257)
Randomized
Does systolic blood pressure decrease during the first 24 hours of acute heart failure admission increase the risk of adverse outcomes?
Hazard Ratio: 1.01 (95% CI 1–1.02)
p-value: p=0.021
A greater decrease in systolic blood pressure during the first 24 hours of acute heart failure admission is associated with increased renal impairment and higher risk of short- and medium-term adverse outcomes.
Early SBP decline in acute HF may identify higher short-term risk; leaves open optimal BP targets pending randomized trials.
AIMS: Changes in systolic blood pressure (SBP) during an admission for acute heart failure (AHF), especially those leading to hypotension, have been suggested to increase the risk for adverse outcomes. METHODS AND RESULTS: We analysed associations of SBP decrease during the first 24 h from randomization with serum creatinine changes at the last time-point available (72 h), using linear regression, and with 30- and 180-day outcomes, using Cox regression, in 1257 patients in the VERITAS study. After multivariable adjustment for baseline SBP, greater SBP decrease at 24 h from randomization was associated with greater creatinine increase at 72 h and greater risk for 30-day all-cause death, worsening heart failure (HF) or HF readmission. The hazard ratio (HR) for each 1 mmHg decrease in SBP at 24 h for 30-day death, worsening HF or HF rehospitalization was 1.01 [95% confidence interval (CI) 1.00-1.02; P = 0.021]. Similarly, the HR for each 1 mmHg decrease in SBP at 24 h for 180-day all-cause mortality was 1.01 (95% CI 1.00-1.03; P = 0.038). The associations between SBP decrease and outcomes did not differ by tezosentan treatment group, although tezosentan treatment was associated with a greater SBP decrease at 24 h. CONCLUSIONS: In the current post hoc analysis, SBP decrease during the first 24 h was associated with increased renal impairment and adverse outcomes at 30 and 180 days. Caution, with special attention to blood pressure monitoring, should be exercised when vasodilating agents are given to AHF patients.
No takes yet. Share an insight, caveat, or question.
Cotter et al. (2017) conducted an RCT in Acute heart failure (n=1,257). 1 mmHg decrease in systolic blood pressure at 24 hours was evaluated on 30-day all-cause death, worsening heart failure (HF) or HF readmission (HR 1.01, 95% CI 1.00-1.02, p=0.021). Each 1 mmHg decrease in systolic blood pressure at 24 hours was associated with increased risk of 30-day death, worsening HF, or HF readmission (HR 1.01; 95% CI 1.00-1.02; P=0.021).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: